Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Humira | Adalimumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | ||
Bystolic | Nebivolol | Hypertension | Do not list at the submitted price | Complete | ||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
Tykerb (in combination with Letrozole) | Lapatinib | Metastatic Breast Cancer | Do not reimburse | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete |